Literature DB >> 4021825

Model building on the basis of Dutch cervical cancer screening data.

J D Habbema, G J van Oortmarssen, J T Lubbe, P J van der Maas.   

Abstract

A mass screening programme for cervical cancer is in progress in three pilot regions in The Netherlands. All women living in these regions aged 35-53 are invited to undergo screening at three-year intervals. The MISCAN simulation model was developed for the analysis and optimization of screening programmes. In this paper the model-based approach to evaluation is first outlined and then illustrated by analysing data from the first two screening rounds in the pilot regions. This analysis resulted in a rather restricted range of data-compatible assumptions for the mean duration of preclinical disease (14-19 yr) and the frequency of spontaneous regression of preinvasive lesions (45-65%), as well as a rather wide sensitivity range for the Pap smear (50-90%). These preliminary findings are compared with those of a previous MISCAN analysis of cervical cancer screening in British Columbia. On the basis of an assumed 18-yr duration, 50% regression and 70% sensitivity, a number of screening policies relating to the same age ranges but with different intervals are compared. Both the analysis and the policy comparisons are preliminary, but the findings are nevertheless reasonable and consistent with those of previous studies. A more complete MISCAN-based analysis of the Dutch screening programme and subsequent optimization of screening policies will be possible when further results become available and a cost-effectiveness analysis procedure has been incorporated into the MISCAN programme.

Entities:  

Mesh:

Year:  1985        PMID: 4021825     DOI: 10.1016/0378-5122(85)90030-1

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  5 in total

Review 1.  Calibration methods used in cancer simulation models and suggested reporting guidelines.

Authors:  Natasha K Stout; Amy B Knudsen; Chung Yin Kong; Pamela M McMahon; G Scott Gazelle
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 2.  Dynamic microsimulation models for health outcomes: a review.

Authors:  Carolyn M Rutter; Alan M Zaslavsky; Eric J Feuer
Journal:  Med Decis Making       Date:  2010-05-18       Impact factor: 2.583

3.  Preventive Pap-smears: balancing costs, risks and benefits.

Authors:  M van Ballegooijen; J D Habbema; G J van Oortmarssen; M A Koopmanschap; J T Lubbe; H M van Agt
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

4.  Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination.

Authors:  Jeremy D Goldhaber-Fiebert; Natasha K Stout; Jesse Ortendahl; Karen M Kuntz; Sue J Goldie; Joshua A Salomon
Journal:  Popul Health Metr       Date:  2007-10-29

5.  Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.

Authors:  Arantzazu Arrospide; Montserrat Rue; Nicolien T van Ravesteyn; Merce Comas; Myriam Soto-Gordoa; Garbiñe Sarriugarte; Javier Mar
Journal:  BMC Cancer       Date:  2016-06-01       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.